atenolol has been researched along with Hypoglycemia in 18 studies
Atenolol: A cardioselective beta-1 adrenergic blocker possessing properties and potency similar to PROPRANOLOL, but without a negative inotropic effect.
atenolol : An ethanolamine compound having a (4-carbamoylmethylphenoxy)methyl group at the 1-position and an N-isopropyl substituent.
Hypoglycemia: A syndrome of abnormally low BLOOD GLUCOSE level. Clinical hypoglycemia has diverse etiologies. Severe hypoglycemia eventually lead to glucose deprivation of the CENTRAL NERVOUS SYSTEM resulting in HUNGER; SWEATING; PARESTHESIA; impaired mental function; SEIZURES; COMA; and even DEATH.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Hypoglycemia was induced in ten healthy male volunteers during medication with atenolol, metoprolol and propranolol." | 5.05 | Blood pressure and pulse response to insulin-induced hypoglycemia during non-selective and selective beta-blockade. ( Anker, E; Bergrem, H; Dahle, K; Jervell, J; Leivestad, T; Myrseth, L; Pape, J; Thaulow, E; Urving, H; vd Lippe, A, 1981) |
| "Our findings suggest that neonates born to mothers exposed to β blockers in late pregnancy, including labetalol, are at elevated risk for neonatal hypoglycemia and bradycardia." | 3.83 | Late Pregnancy β Blocker Exposure and Risks of Neonatal Hypoglycemia and Bradycardia. ( Bateman, BT; Desai, RJ; Fischer, MA; Hernandez-Diaz, S; Huybrechts, KF; Maeda, A; Mogun, H; Patorno, E; Seely, EW, 2016) |
| "The effects of nonselective beta-blockade (propranolol) and beta-1-selective blockade (atenolol) on glucose metabolism during insulin-induced hypoglycemia were studied in eight normal subjects during constant infusion of 3-[3H]glucose." | 3.66 | Effects of nonselective and beta-1-selective blockade on glucose metabolism and hormone responses during insulin-induced hypoglycemia in normal man. ( Christensen, NJ; Lauridsen, UB; Lyngsøe, J, 1983) |
| "1148 hypertensive patients with type 2 diabetes (mean age 56, mean blood pressure at entry 160/94 mm Hg); 758 patients were allocated to tight control of blood pressure and 390 patients to less tight control with a median follow up of 8." | 2.69 | Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. ( , 1998) |
| "Captopril and atenolol were equally effective in reducing blood pressure to a mean of 144/83 mm Hg and 143/81 mm Hg respectively, with a similar proportion of patients (27% and 31%) requiring three or more antihypertensive treatments." | 2.69 | Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. UK Prospective Diabetes Study Group. ( , 1998) |
| "Pre-treatment with propranolol LA resulted in a significant pressor response and a bradycardia during hypoglycaemia." | 2.67 | Beta-adrenoceptor blockade and hypoglycaemia. A randomised, double-blind, placebo controlled comparison of metoprolol CR, atenolol and propranolol LA in normal subjects. ( Heller, SR; Kerr, D; MacDonald, IA; Tattersall, RB, 1990) |
| "Atenolol treatment abolished almost completely these hemodynamic changes." | 1.26 | [Effect of pretreatment with atenolol and propranolol on sympatho-adrenal and cardiovascular responses to acute insulin-induced hypoglycaemia in the hypertensive patient]. ( Cannella, G; Cesura, AM; Giambelli, A; Maiorca, R; Picotti, GB; Scolari, F; Tosoni, S, 1982) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 6 (33.33) | 18.7374 |
| 1990's | 5 (27.78) | 18.2507 |
| 2000's | 3 (16.67) | 29.6817 |
| 2010's | 3 (16.67) | 24.3611 |
| 2020's | 1 (5.56) | 2.80 |
| Authors | Studies |
|---|---|
| Aviran Barak, N | 1 |
| Reno, CM | 1 |
| Skinner, A | 1 |
| Bayles, J | 1 |
| Chen, YS | 1 |
| Daphna-Iken, D | 1 |
| Fisher, SJ | 1 |
| Mani, BK | 1 |
| Osborne-Lawrence, S | 1 |
| Vijayaraghavan, P | 1 |
| Hepler, C | 1 |
| Zigman, JM | 1 |
| Bateman, BT | 1 |
| Patorno, E | 1 |
| Desai, RJ | 1 |
| Seely, EW | 1 |
| Mogun, H | 1 |
| Maeda, A | 1 |
| Fischer, MA | 1 |
| Hernandez-Diaz, S | 1 |
| Huybrechts, KF | 1 |
| Robinson, RT | 2 |
| Harris, ND | 2 |
| Ireland, RH | 1 |
| Lee, S | 1 |
| Newman, C | 1 |
| Heller, SR | 3 |
| Lee, SP | 1 |
| Davies, C | 1 |
| Ireland, R | 1 |
| Macdonald, IA | 2 |
| Pape, J | 1 |
| Jervell, J | 1 |
| Anker, E | 1 |
| Bergrem, H | 1 |
| Dahle, K | 1 |
| Leivestad, T | 1 |
| vd Lippe, A | 1 |
| Myrseth, L | 1 |
| Thaulow, E | 1 |
| Urving, H | 1 |
| Lauridsen, UB | 1 |
| Christensen, NJ | 1 |
| Lyngsøe, J | 1 |
| Cannella, G | 1 |
| Picotti, GB | 1 |
| Giambelli, A | 1 |
| Scolari, F | 1 |
| Cesura, AM | 1 |
| Tosoni, S | 1 |
| Maiorca, R | 1 |
| Thoma, ME | 1 |
| Glauser, J | 1 |
| Genuth, S | 1 |
| Levinson, PD | 1 |
| Deacon, SP | 2 |
| Barnett, D | 2 |
| Karunanayake, A | 1 |
| Kerr, D | 1 |
| Tattersall, RB | 1 |
| Abbasi, IA | 1 |
| Sorsby, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Predicting Hypoglycaemia and Arrhythmias in the Vulnerable Patient With Diabetes and Chronic Kidney Disease - Validation Study[NCT02778269] | 7 participants (Actual) | Interventional | 2016-06-30 | Completed | |||
| FLAT-SUGAR: FLuctuATion Reduction With inSULin and Glp-1 Added togetheR[NCT01524705] | Phase 4 | 102 participants (Actual) | Interventional | 2012-08-31 | Completed | ||
| Effect of Deferoxamine on Wound Healing Rate in Patients With Diabetes Foot Ulcers[NCT03137966] | Phase 2 | 174 participants (Anticipated) | Interventional | 2022-12-30 | Not yet recruiting | ||
| Does Glycated Hemoglobin Variability in Type 2 Diabetes Differ Depending on the Diabetes Treatment Threshold Used in the Qatari Population: Implication on Diabetes Complication Risk?[NCT02879409] | 150 participants (Anticipated) | Interventional | 2016-11-30 | Active, not recruiting | |||
| Assessment of Efficacy and Safety of Thioctic Acid in the Oral Treatment of Symptomatic Diabetic Neuropathy (SYDNEY 2) Randomised, Double-blind,Placebo-controlled Multicentre Trial With 4 Parallel Groups[NCT00328601] | Phase 3 | 170 participants | Interventional | 2005-02-28 | Completed | ||
| The Glooko Diabetes Mobile Monitoring and Management Advantage Study[NCT02974816] | 197 participants (Actual) | Interventional | 2017-05-15 | Completed | |||
| Propranolol as a Treatment for Impaired Awareness of Hypoglycemia in Type 1 Diabetes[NCT03161964] | Phase 2 | 2 participants (Actual) | Interventional | 2017-10-19 | Terminated (stopped due to Statistical power could not be achieved due to low enrollment.) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The change in the coefficient of variation (CV) of continuous glucose readings, as assessed by Continuous Glucose Monitoring (CGM) (NCT01524705)
Timeframe: At baseline, 6 months of intervention
| Intervention | percentage (Mean) |
|---|---|
| Insulin Glargine, Metformin, Exenatide | -2.43 |
| Insulin Glargine, Metformin, Prandial Insulin | 0.44 |
% of glycosylated hemoglobin in whole blood at 26 weeks (NCT01524705)
Timeframe: Baseline vs 26 weeks
| Intervention | % of HbA1C (Mean) |
|---|---|
| Insulin Glargine, Metformin, Exenatide | 7.1 |
| Insulin Glargine, Metformin, Prandial Insulin | 7.2 |
Severe hypoglycemia-documented glucose <50mg/dl (participant journal), and hypoglycemic attacks requiring hospitalization, or treatment by emergency personnel. (NCT01524705)
Timeframe: 26 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Insulin Glargine, Metformin, Exenatide | 0 |
| Insulin Glargine, Metformin, Prandial Insulin | 0 |
Weight in kg at 26 weeks minus weight at baseline. (NCT01524705)
Timeframe: Baseline vs 26 weeks
| Intervention | kg (Mean) |
|---|---|
| Insulin Glargine, Metformin, Exenatide | -4.8 |
| Insulin Glargine, Metformin, Prandial Insulin | 0.7 |
1 review available for atenolol and Hypoglycemia
| Article | Year |
|---|---|
Beta-blockers, diabetes, and hypoglycemia: risky business?
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Aten | 2001 |
7 trials available for atenolol and Hypoglycemia
| Article | Year |
|---|---|
Blood pressure and pulse response to insulin-induced hypoglycemia during non-selective and selective beta-blockade.
Topics: Adrenergic beta-Antagonists; Adult; Atenolol; Blood Pressure; Heart Rate; Humans; Hypoglycemia; Insu | 1981 |
Hypertension in Diabetes Study IV. Therapeutic requirements to maintain tight blood pressure control.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents | 1996 |
Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group.
Topics: Adrenergic beta-Antagonists; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive | 1998 |
Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group.
Topics: Adrenergic beta-Antagonists; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive | 1998 |
Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group.
Topics: Adrenergic beta-Antagonists; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive | 1998 |
Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group.
Topics: Adrenergic beta-Antagonists; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive | 1998 |
Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group.
Topics: Adrenergic beta-Antagonists; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive | 1998 |
Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group.
Topics: Adrenergic beta-Antagonists; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive | 1998 |
Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group.
Topics: Adrenergic beta-Antagonists; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive | 1998 |
Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group.
Topics: Adrenergic beta-Antagonists; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive | 1998 |
Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group.
Topics: Adrenergic beta-Antagonists; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive | 1998 |
Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group.
Topics: Adrenergic beta-Antagonists; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive | 1998 |
Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group.
Topics: Adrenergic beta-Antagonists; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive | 1998 |
Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group.
Topics: Adrenergic beta-Antagonists; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive | 1998 |
Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group.
Topics: Adrenergic beta-Antagonists; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive | 1998 |
Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group.
Topics: Adrenergic beta-Antagonists; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive | 1998 |
Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group.
Topics: Adrenergic beta-Antagonists; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive | 1998 |
Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group.
Topics: Adrenergic beta-Antagonists; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive | 1998 |
Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. UK Prospective Diabetes Study Group.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Aten | 1998 |
Comparison of atenolol and propranolol during insulin-induced hypoglycaemia.
Topics: Adrenergic beta-Antagonists; Adult; Atenolol; Blood Glucose; Clinical Trials as Topic; Depression, C | 1976 |
Acebutolol, atenolol, and propranolol and metabolic responses to acute hypoglycaemia in diabetics.
Topics: Acebutolol; Adolescent; Adult; Atenolol; Blood Glucose; Clinical Trials as Topic; Diabetes Complicat | 1977 |
Beta-adrenoceptor blockade and hypoglycaemia. A randomised, double-blind, placebo controlled comparison of metoprolol CR, atenolol and propranolol LA in normal subjects.
Topics: Adrenergic beta-Antagonists; Adult; Atenolol; Blood Pressure; Cognition; Double-Blind Method; Female | 1990 |
10 other studies available for atenolol and Hypoglycemia
| Article | Year |
|---|---|
[MERCAPTIZOL INDUCED HYPOGLYCEMIA - A CASE REPORT].
Topics: Adult; Atenolol; Autoantibodies; C-Peptide; Female; Humans; Hypoglycemia; Insulin Antibodies; Iodine | 2022 |
Severe hypoglycemia-induced sudden death is mediated by both cardiac arrhythmias and seizures.
Topics: Adrenergic beta-1 Receptor Antagonists; Animals; Anti-Arrhythmia Agents; Anticonvulsants; Arrhythmia | 2018 |
β1-Adrenergic receptor deficiency in ghrelin-expressing cells causes hypoglycemia in susceptible individuals.
Topics: Animals; Atenolol; Blood Glucose; Body Weight; Caloric Restriction; Female; Gastric Mucosa; Gene Del | 2016 |
Late Pregnancy β Blocker Exposure and Risks of Neonatal Hypoglycemia and Bradycardia.
Topics: Adrenergic beta-Antagonists; Atenolol; Bradycardia; Cohort Studies; Female; Humans; Hypertension; Hy | 2016 |
Mechanisms of abnormal cardiac repolarization during insulin-induced hypoglycemia.
Topics: Adrenergic beta-Antagonists; Atenolol; Blood Glucose; Blood Pressure; Epinephrine; Glucose Clamp Tec | 2003 |
Mechanisms of abnormal cardiac repolarization during insulin-induced hypoglycemia.
Topics: Adrenergic beta-Antagonists; Atenolol; Blood Glucose; Blood Pressure; Epinephrine; Glucose Clamp Tec | 2003 |
Mechanisms of abnormal cardiac repolarization during insulin-induced hypoglycemia.
Topics: Adrenergic beta-Antagonists; Atenolol; Blood Glucose; Blood Pressure; Epinephrine; Glucose Clamp Tec | 2003 |
Mechanisms of abnormal cardiac repolarization during insulin-induced hypoglycemia.
Topics: Adrenergic beta-Antagonists; Atenolol; Blood Glucose; Blood Pressure; Epinephrine; Glucose Clamp Tec | 2003 |
Effect of atenolol on QTc interval lengthening during hypoglycaemia in type 1 diabetes.
Topics: Adrenergic beta-Antagonists; Atenolol; Blood Pressure; Diabetes Mellitus, Type 1; Electrocardiograph | 2005 |
Effects of nonselective and beta-1-selective blockade on glucose metabolism and hormone responses during insulin-induced hypoglycemia in normal man.
Topics: Adult; Atenolol; Blood Glucose; Epinephrine; Fatty Acids, Nonesterified; Glucagon; Growth Hormone; H | 1983 |
[Effect of pretreatment with atenolol and propranolol on sympatho-adrenal and cardiovascular responses to acute insulin-induced hypoglycaemia in the hypertensive patient].
Topics: Adult; Atenolol; Blood Glucose; Blood Pressure; Catecholamines; Female; Heart Rate; Hemodynamics; Hu | 1982 |
Persistent hypoglycemia and hyperinsulinemia: caution in using glucagon.
Topics: Adrenergic beta-Antagonists; Alcoholism; Atenolol; Glucagon; Glyburide; Humans; Hyperinsulinism; Hyp | 1996 |
Prolonged toxicity from atenolol overdose in an adolescent.
Topics: Adolescent; Atenolol; Bradycardia; Female; Humans; Hypoglycemia; Hypotension; Suicide, Attempted | 1986 |